DR. JEREMY DURACK AND DR. JOHN SIMPSON TO JOIN CORDIS-X INNOVATION ACCELERATOR
Dr. Simpson, a world-renowned cardiologist, is credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA) and is known for pioneering interventional cardiology as it exists today. As Senior Advisor to Cordis-X, Dr. Simpson brings decades of scientific and commercial experience. He has founded and successfully transacted multiple MedTech companies, including ACS and DVI (both acquired by Eli Lilly), CVIS (acquired by Boston Scientific), Perclose (acquired by Abbott), Lumend (acquired by Cordis), and Fox Hollow (acquired by ev3, which is now part of Medtronic).
Dr. Simpson received his PhD in biomedical sciences from the University of Texas, his MD from Duke University, and completed his fellowship in interventional cardiology at Stanford University. A member of the American College of Physicians and fellow of the American College of Cardiology, Dr. Simpson has published on a wide variety of medical subjects and lectured extensively throughout the world.
Dr. Jeremy Durack, an interventional radiologist and former Vice-Chair of Radiology at Memorial Sloan Kettering Cancer Center, will serve as Chief Clinical Officer for Cordis-X. He is renowned for his work in vascular and interventional radiology, with expertise in a wide range of minimally invasive procedures and particular interest in the treatment of genitourinary cancers and venous thrombosis.
Dr. Durack received his MD from Stanford University School of Medicine and completed his residency and fellowship at UCSF School of Medicine. He has been a leader in the Society of Interventional Radiology and brings a wealth of international research experience to the team.
“The collective capabilities of Ajax Health, Cordis-X, and Cordis are creating a tractor beam for the best and brightest,” said Dr. Durack. “It’s not just recruiting engineers and physicians motivated to improve how we prevent and treat cardiovascular disease, but also to develop new ways of thinking about fields such as Interventional Oncology as well as how we can address global health disparities.”
The appointments of Dr. Simpson and Dr. Durack signal an aggressive effort by Cordis-X to recruit some of the most successful industry innovators to its team.
“I have great admiration for Cordis,” said Dr. Simpson. “They created the first catheter I ever used for diagnostic angiography in humans. Cordis products were state of the art, ahead of everyone else. I look forward to helping the organization push the edges of innovation and create new products we’ll be talking about decades from now.”
For more information contact [email protected]
Media contact:
David Beylik, Associate, Ajax Health & Cordis-X
(949) 939-8913
[email protected]
About Ajax Health
Ajax Health builds, invests in, and scales disruptive healthcare technologies. The Ajax team has a proven track record of helping companies of all sizes, stages, and structures achieve their full value-creation potential. Ajax is headquartered in Menlo Park, CA.
About Cordis
Cordis is a global leader in the development and manufacturing of interventional vascular technologies, with a 60-year history of treating millions of patients and pioneering life-saving products.
About Cordis-X
Cordis-X is an independent innovation accelerator with a streamlined go-to-market model built for speed, agility, and value maximization. Cordis-X works with Ajax Health and Cordis to create the solutions and technologies of tomorrow through rapid development, evaluation, and commercialization.
SOURCE Ajax Health